Caribou Biosciences 

 

Tim Kelly, Chief Technology Officer 

Oct. 8 | 4:30pm | FLW Ballroom G 

Berkeley, CA 

(NASDAQ: CRBU) 

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. 

www.cariboubio.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions